K Number
K070353
Device Name
KELSEY INTERSITITAL LASER THERAPY SYSTEM
Manufacturer
Date Cleared
2007-05-02

(85 days)

Product Code
Regulation Number
878.4810
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP Authorized
Intended Use
The Kelsey Interstitial Laser Therapy System is indicated for the treatment of fibroadenomas of the breast, with tumor sizes up to 20 mm; and for general surgery procedures including incision, excision and ablation of soft tissues; and coagulative necrosis and interstitial laser coagulation of soft tissue.
Device Description
The Kelsey Interstitial Laser Therapy system consists of the following: - One laser probe, a 14 gauge needle, 304 stainless steel with one (1) thermistor attached. - One temperature probe, a 14 gauge needle, 304 stainless steel with five (5) thermistors attached. - Thermistor temperature to digital converter. - Syringe infusion pump capable of accurately infusing a normal saline solution at variable flow rates to 1 cc per minute, continuously adjustable, including bolus function. - Laser diode source, 1-8 watts, 805 nominal nanometer wavelength. - Storage cart. - Personal computer running Windows XP with Service Pack 2, or better, including monitor and keyboard.
More Information

Diomed 15 Plus, Indigo 830, Indigo Diffuser Tip Fiberoptic w/Temp Sensing Option, Cryocarc™ Surgical System

Not Found

No
The device description lists standard medical device components and a personal computer running Windows XP, with no mention of AI/ML algorithms or capabilities. The "Mentions AI, DNN, or ML" field is explicitly marked as "Not Found".

Yes
The device is indicated for the treatment of fibroadenomas and for general surgery procedures involving incision, excision, ablation of soft tissues, and coagulative necrosis, which are all therapeutic interventions.

No

This device is described as a "Therapy System" indicated for the "treatment" of fibroadenomas and for general surgery "procedures including incision, excision and ablation of soft tissues". Its components and described functions, such as laser sources and infusion pumps, are consistent with therapeutic interventions rather than diagnostic processes.

No

The device description clearly lists multiple hardware components including laser probes, temperature probes, a syringe infusion pump, a laser diode source, and a storage cart, in addition to a personal computer.

Based on the provided information, the Kelsey Interstitial Laser Therapy System is not an In Vitro Diagnostic (IVD).

Here's why:

  • Intended Use: The intended use clearly describes a therapeutic procedure performed directly on the patient's body (treatment of fibroadenomas, general surgery procedures, soft tissue ablation and coagulation). IVDs are used to examine specimens taken from the body (like blood, urine, tissue samples) to provide information about a patient's health status.
  • Device Description: The components listed are all designed for delivering energy (laser) and monitoring temperature within the body, or for supporting this process. There are no components mentioned that would be used for analyzing biological samples.
  • Performance Studies: The performance studies described focus on the safety and effectiveness of the device for tissue ablation, which is a therapeutic outcome, not a diagnostic one.

Therefore, the Kelsey Interstitial Laser Therapy System is a therapeutic device, not an IVD.

N/A

Intended Use / Indications for Use

The intended use for the Kelsey Interstitial Laser Therapy System is the predicate devices. Its intended use is as a surgical instrument in the excision of external tumors and lesions, complete and partial resection of internal organs, treatment of tumors and lesions, skin incision and tissue dissection and ablation.

The Kelsey Interstitial Laser Therapy System is indicated for the treatment of fibroadenomas of the breast, with tumor sizes up to 20 mm; and for gencral surgery procedures including incision, excision and ablation of soft tissues; and coagulative necrosis and interstitial laser coagulation of soft tissue.

Product codes

GEX

Device Description

The Kelsey Interstitial Laser Therapy system consists of the following:

  • One laser probe, a 14 gauge needle, 304 stainless steel with one (1) thermistor attached.
  • One temperature probe, a 14 gauge needle, 304 stainless steel with five (5) thermistors attached.
  • Thermistor temperature to digital converter.
  • Syringe infusion pump capable of accurately infusing a normal saline solution at variable flow rates to 1 cc per minute, continuously adjustable, including bolus function.
  • Laser diode source, 1-8 watts, 805 nominal nanometer wavelength.
  • Storage cart.
  • Personal computer running Windows XP with Service Pack 2, or better, including monitor and keyboard.

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Breast (for fibroadenomas), external tumors and lesions, internal organs, soft tissues.

Indicated Patient Age Range

Not Found

Intended User / Care Setting

Not Found

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Bench and clinical tcsting demonstrated that the use of the Kelsey ILT device for the ablation of breast fibroadenoma tissue is safe and effective.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s)

Diomed 15 Plus, Indigo 830, Indigo Diffuser Tip Fiberoptic w/Temp Sensing Option, Cryocarc™ Surgical System

Reference Device(s)

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information

Not Found

§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.

(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.

0

Kelsey, Inc. 510(k) Submission - ILT January 31, 2007

K070353

3 510k Summary

3.1 Company

Kelscy, Inc. 20 South Clark Street, Suite 1600 Chicago, IL 60603

3.2 Contact

Paul Ketteridge Regulatory Consultant to Kelsey 303 Patleigh Rd Catonsville, MD 21228 (443) 729-0836 Voice (443) 729-0826 Fax p.kett(a)comcast.net

3.3 Date Prepared

January 24, 2007

3.4 Device Name

Trade Name:Kelsey Interstitial Laser Therapy System
Classification Name:Laser powered surgical instrument

3.5 Predicate Devices

Diomed 15 Plus
Indigo 830
Indigo Diffuser Tip Fiberoptic w/Temp Sensing Option
Cryocarc™ Surgical System

3.6 Device Description

The Kelsey Interstitial Laser Therapy system consists of the following:

  • One laser probe, a 14 gauge needle, 304 stainless steel with one (1) thermistor attached. 트
  • 트 One temperature probe, a 14 gauge needle, 304 stainless steel with five (5) thermistors attached.
  • 제 Thermistor temperature to digital converter.
  • . Syringe infusion pump capable of accurately infusing a normal saline solution at variable flow rates to 1 cc per minute, continuously adjustable, including bolus function.
  • . Laser diode source, 1-8 watts, 805 nominal nanometer wavelength.
  • 해 Storage cart.

MAY - 2 2007

1

Kelsey, Inc. 510(k) Submission - ILT January 31, 2007

$$
\langle \circ \circ \circ \circ \rangle$$

  • . Personal computer running Windows XP with Service Pack 2, or better, including monitor and keyboard.

3.7 Intended Use

The intended use for the Kelsey Interstitial Laser Therapy System is the predicate devices. Its intended use is as a surgical instrument in the excision of external tumors and lesions, complete and partial resection of internal organs, treatment of tumors and lesions, skin incision and tissue dissection and ablation.

3.8 Indications for Use

The Kelsey Interstitial Laser Therapy System is indicated for the treatment of fibroadenomas of the breast, with tumor sizes up to 20 mm; and for gencral surgery procedures including incision, excision and ablation of soft tissues; and coagulative necrosis and interstitial laser coagulation of soft tissue.

3.9 Comparison of Technological Characteristics

The Kelsey Interstitial Laser Therapy System is a self-contained surgical lascr that generates near-infrared laser radiation. A fiber optic delivery system is coupled to the laser to deliver laser radiation to the target tissue. These technologic characteristics are shared with the previously identified predicate devices.

3.10Performance Data

Bench and clinical tcsting demonstrated that the use of the Kelsey ILT device for the ablation of breast fibroadenoma tissue is safe and effective.

2

Image /page/2/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized eagle with its wings spread, and the words "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" are arranged in a circular pattern around the eagle. The logo is black and white.

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Kelsey, Inc. % Mr. Paul Ketteridge Regulatory Consultant 303 Patleigh Road Catonsville, Maryland 21228

MAY - 2 2007

Re: K070353

Trade/Device Name: Kelsey Interstitial Laser Therapy System Regulation Number: 21 CFR 878.4810 Regulation Name: Laser surgical instrument for use in general and plastic surgery and in dermatology Regulatory Class: II Product Code: GEX Dated: January 31, 2007 Received: February 6, 2007

Dear Mr. Ketteridge:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

3

Page 2 – Mr. Paul Ketteridge

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson
Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

4

Kelsey, Inc. 510(k) Submission - ILT January 31, 2007

Indications for Use 2

510(k) Number (if known): K070353

Device Name: Kelsey Interstitial Laser Therapy System

Indications for Use:

The Kelsey Interstitial Laser Therapy System is indicated for the treatment of fibroadenomas of the breast, with tumor sizes up to 20 mm; and for general surgery procedures including incision, excision and ablation of soft tissues; and coagulative necrosis and interstitial laser coagulation of soft tissue.

Prescription Use (21 CFR 801 Subpart D) X

And/Or

Over-The-Counter Use (21 CFR 807 Subpart C)

Do Not Write Below This Line – Continue on Another Page if Needed

Concurrence of CDRH, Office of Device Evaluation (ODE)

Dehn
(Division Sign-Off)

Division of General, Restorative, and Neurological Devices

510(k) Number L070353

Page 7